BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18704591)

  • 1. Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment.
    Graf N; Herrmann K; den Hollander J; Fend F; Schuster T; Wester HJ; Senekowitsch-Schmidtke R; zum Büschenfelde CM; Peschel C; Schwaiger M; Dechow T; Buck AK
    Mol Imaging Biol; 2008; 10(6):349-55. PubMed ID: 18704591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner.
    Graf N; Herrmann K; Numberger B; Zwisler D; Aichler M; Feuchtinger A; Schuster T; Wester HJ; Senekowitsch-Schmidtke R; Peschel C; Schwaiger M; Keller U; Dechow T; Buck AK
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):34-43. PubMed ID: 23053327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment.
    Herrmann K; Buck AK; Schuster T; Junger A; Wieder HA; Graf N; Ringshausen I; Rudelius M; Wester HJ; Schwaiger M; Keller U; Dechow T
    J Nucl Med; 2011 May; 52(5):690-6. PubMed ID: 21498532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
    Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
    Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.
    Schöder H; Zelenetz AD; Hamlin P; Gavane S; Horwitz S; Matasar M; Moskowitz A; Noy A; Palomba L; Portlock C; Straus D; Grewal R; Migliacci JC; Larson SM; Moskowitz CH
    J Nucl Med; 2016 May; 57(5):728-34. PubMed ID: 26719374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models.
    Apisarnthanarax S; Alauddin MM; Mourtada F; Ariga H; Raju U; Mawlawi O; Han D; Bornmann WG; Ajani JA; Milas L; Gelovani JG; Chao KS
    Clin Cancer Res; 2006 Aug; 12(15):4590-7. PubMed ID: 16899606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT.
    Buck AK; Kratochwil C; Glatting G; Juweid M; Bommer M; Tepsic D; Vogg AT; Mattfeldt T; Neumaier B; Möller P; Reske SN
    Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1775-82. PubMed ID: 17541585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depicting Changes in Tumor Biology in Response to Cetuximab Monotherapy or Combination Therapy by Apoptosis and Proliferation Imaging Using
    Heinzmann K; Nguyen QD; Honess D; Smith DM; Stribbling S; Brickute D; Barnes C; Griffiths J; Aboagye E
    J Nucl Med; 2018 Oct; 59(10):1558-1565. PubMed ID: 29794225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease.
    Wagner M; Seitz U; Buck A; Neumaier B; Schultheiss S; Bangerter M; Bommer M; Leithäuser F; Wawra E; Munzert G; Reske SN
    Cancer Res; 2003 May; 63(10):2681-7. PubMed ID: 12750297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice.
    Munk Jensen M; Erichsen KD; Björkling F; Madsen J; Jensen PB; Sehested M; Højgaard L; Kjær A
    PLoS One; 2012; 7(11):e50618. PubMed ID: 23226334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of 3'-deoxy-3'-[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma.
    Lawrence J; Vanderhoek M; Barbee D; Jeraj R; Tumas DB; Vail DM
    Vet Radiol Ultrasound; 2009; 50(6):660-8. PubMed ID: 19999354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo.
    Leyton J; Latigo JR; Perumal M; Dhaliwal H; He Q; Aboagye EO
    Cancer Res; 2005 May; 65(10):4202-10. PubMed ID: 15899811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
    Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
    J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex as a Biologic Variable in Preclinical Imaging Research: Initial Observations with
    Chan SR; Salem K; Jeffery J; Powers GL; Yan Y; Shoghi KI; Mahajan AM; Fowler AM
    J Nucl Med; 2018 May; 59(5):833-838. PubMed ID: 29217733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
    Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
    Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy.
    Li Z; Graf N; Herrmann K; Jünger A; Aichler M; Feuchtinger A; Baumgart A; Walch A; Peschel C; Schwaiger M; Buck A; Keller U; Dechow T
    Cancer Res; 2012 Oct; 72(19):5014-24. PubMed ID: 22875026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Value of Early-Stage Uptake of 3'-Deoxy-3'-18F-Fluorothymidine in Cancer Cells Treated with Charged Particle Irradiation.
    Lin C; Kume K; Mori T; Martinez ME; Okazawa H; Kiyono Y
    J Nucl Med; 2015 Jun; 56(6):945-50. PubMed ID: 25766892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma.
    Herrmann K; Wieder HA; Buck AK; Schöffel M; Krause BJ; Fend F; Schuster T; Meyer zum Büschenfelde C; Wester HJ; Duyster J; Peschel C; Schwaiger M; Dechow T
    Clin Cancer Res; 2007 Jun; 13(12):3552-8. PubMed ID: 17575218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of [18F]-tracers in various experimental tumor models by PET imaging and identification of an early response biomarker for the novel microtubule stabilizer patupilone.
    Ebenhan T; Honer M; Ametamey SM; Schubiger PA; Becquet M; Ferretti S; Cannet C; Rausch M; McSheehy PM
    Mol Imaging Biol; 2009; 11(5):308-21. PubMed ID: 19462209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.
    Ullrich R; Backes H; Li H; Kracht L; Miletic H; Kesper K; Neumaier B; Heiss WD; Wienhard K; Jacobs AH
    Clin Cancer Res; 2008 Apr; 14(7):2049-55. PubMed ID: 18381944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.